Reality Check

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

A review of market access for type 2 diabetes (DPP4 and combo) treatments shows that under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions. Around 21% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Colorectal Cancer

A review of market access for colorectal cancer treatments shows that under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions. Around 28% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Cystic Fibrosis

A review of market access for cystic fibrosis treatments shows that under the pharmacy benefit, about 65% of the lives under commercial formularies are covered with utilization management restrictions. Around 32% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Chronic Lymphocytic Leukemia

A review of market access for chronic lymphocytic leukemia treatments shows that under the pharmacy benefit, about 49% of the lives under commercial formularies are covered with utilization management restrictions. Around 32% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Hepatocellular Carcinoma

Payer Coverage: A review of market access for hepatocellular carcinoma treatments shows that under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management r...
0 Comments

MMIT Reality Check on Psoriasis

Payer Coverage: A review of market access for psoriasis treatments shows that under the pharmacy benefit, about 70% of the lives under commercial formularies are covered with utilization management restrictions. Ar...
0 Comments

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Payer Coverage: A review of market access for hemophilia A (factor VIII) treatments shows that under the pharmacy benefit, about 38% of the lives under commercial formularies are covered with utilization management...
0 Comments

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Payer Coverage: A review of market access for diffuse large B-cell lymphoma treatments shows that under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization managem...
0 Comments

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Payer Coverage: A review of market access for multiple sclerosis treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered with utilization management restric...
0 Comments

MMIT Reality Check on Multiple Myeloma (Oct 2021)

Payer Coverage: A review of market access for multiple myeloma treatments shows that under the pharmacy benefit, about half of the lives under commercial formularies are covered with utilization management restrict...
0 Comments